Feasibility of high-dose paclitaxel in the conditioning regimen for autologous hematopoietic transplantation.

被引：0
|
作者：
Perez-Calvo, J
Fernández-Hidalgo, O
Aramendía, JM
Rebollo, J
Salgado, E
Rifón, JJ
Prósper, F
Rocha, E
Martín-Algarra, S
机构：
[1] Univ Navarra Clin, Pamplona, Spain
[2] Clin San Miguel, Pamplona, Spain
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5453
引用
收藏
页码：431B / 431B
页数：1
相关论文
共 50 条
  • [21] High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
    D Sivaraj
    W Bacon
    G D Long
    D A Rizzieri
    M E Horwitz
    K M Sullivan
    Y Kang
    Z Li
    N J Chao
    C Gasparetto
    Bone Marrow Transplantation, 2018, 53 : 34 - 38
  • [22] High-dose chemotherapy followed by autologous stem-cell transplantation for Hodgkin disease using CVB as conditioning regimen
    Avila, R. A.
    Valdez, J. A.
    Caeiro, G.
    Basquiera, A. L.
    Sturich, A. G.
    Berretta, A. R.
    Garcia, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BONE MARROW TRANSPLANTATION, 2018, 53 : 262 - 263
  • [24] High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
    Sivaraj, D.
    Bacon, W.
    Long, G. D.
    Rizzieri, D. A.
    Horwitz, M. E.
    Sullivan, K. M.
    Kang, Y.
    Li, Z.
    Chao, N. J.
    Gasparetto, C.
    BONE MARROW TRANSPLANTATION, 2018, 53 (01) : 34 - 38
  • [25] Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
    Smith, S. D.
    Bolwell, B. J.
    Rybicki, L. A.
    Brown, S.
    Dean, R.
    Kalaycio, M.
    Sobecks, R.
    Andresen, S.
    Hsi, E. D.
    Pohlman, B.
    Sweetenham, J. W.
    BONE MARROW TRANSPLANTATION, 2007, 40 (03) : 239 - 243
  • [26] Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
    S D Smith
    B J Bolwell
    L A Rybicki
    S Brown
    R Dean
    M Kalaycio
    R Sobecks
    S Andresen
    E D Hsi
    B Pohlman
    J W Sweetenham
    Bone Marrow Transplantation, 2007, 40 : 239 - 243
  • [27] Herpes zoster after high-dose chemotherapy and autologous stem cell transplantation.
    Fetscher, S
    Technau, K
    Lange, W
    BONE MARROW TRANSPLANTATION, 1999, 23 : S114 - S114
  • [28] Infectious complications after high-dose chemotherapy and autologous stem cell transplantation.
    Reich, G
    Mapara, MY
    Reichardt, P
    Dörken, B
    Maschmeyer, G
    BLOOD, 1998, 92 (10) : 337B - 337B
  • [29] Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
    Aypar, Eda
    Izzettin, Fikret Vehbi
    Aki, Sahika Zeynep
    Sancar, Mesut
    Yegin, Zeynep Arzu
    Turkoz-Sucak, Gulsan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (04) : 281 - 289
  • [30] Bortezomib after high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with multiple myeloma: A comparison with the historical conditioning regimen with melphalan alone
    Ferini, G. A.
    Arbelbide, J. A.
    Basquiera, A. L.
    Nucifora, E.
    Schutz, N.
    Otero, V.
    Fantl, D.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S461 - S462
12345